Overview Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease Status: Completed Trial end date: 2014-06-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate PK, PD and safety of a single oral dose of MT-1303 in subjects with Crohn's disease. Phase: Phase 1 Details Lead Sponsor: Mitsubishi Tanabe Pharma Corporation